Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09ADT
|
||||
| Former ID |
DNC000130
|
||||
| Drug Name |
ABT-418
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Discontinued in Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C9H14N2O
|
||||
| Canonical SMILES |
CC1=NOC(=C1)C2CCCN2C
|
||||
| InChI |
1S/C9H14N2O/c1-7-6-9(12-10-7)8-4-3-5-11(8)2/h6,8H,3-5H2,1-2H3/t8-/m0/s1
|
||||
| InChIKey |
ILLGYRJAYAAAEW-QMMMGPOBSA-N
|
||||
| CAS Number |
CAS 147402-53-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Neuronal acetylcholine receptor protein, alpha-4 chain | Target Info | Agonist | [2] | |
| Nicotinic acetylcholine receptor | Target Info | Agonist | [3] | ||
| Neuronal acetylcholine receptor protein, beta-2 chain | Target Info | Agonist | [4], [2] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Cholinergic synapse | |||||
| Nicotine addictionhsa04080:Neuroactive ligand-receptor interaction | |||||
| Nicotine addiction | |||||
| PANTHER Pathway | Nicotinic acetylcholine receptor signaling pathway | ||||
| Nicotine pharmacodynamics pathwayP00044:Nicotinic acetylcholine receptor signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Highly sodium permeable acetylcholine nicotinic receptors | ||||
| Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | |||||
| Highly calcium permeable nicotinic acetylcholine receptorsR-HSA-629587:Highly sodium permeable acetylcholine nicotinic receptors | |||||
| Highly calcium permeable nicotinic acetylcholine receptors | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Nicotine Activity on Dopaminergic NeuronsWP706:SIDS Susceptibility Pathways | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004036) | ||||
| REF 2 | (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther. 1994 Jul;270(1):319-28. | ||||
| REF 3 | Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats. Psychopharmacology (Berl). 1999 May;144(2):175-82. | ||||
| REF 4 | Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res. 2000 Mar-Apr;31(2):131-44. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.